
|Videos|August 6, 2021
Dr. Ketan K. Badani discusses the significance of PSMA agents
Author(s)Urology Times staff
“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.
Advertisement
In this video, Ketan K. Badani, MD, shares a key takeaway in prostate cancer from the 2021 ASCO annual meeting. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












